Vitamin K (phytonadione, phytomenadione): Drug information

(For additional information see "Vitamin K (phytonadione, phytomenadione): Patient drug information" and see "Vitamin K (phytonadione, phytomenadione): Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)

ALERT: US Boxed Warning

Hypersensitivity reactions with IV and IM use:

Fatal hypersensitivity reactions, including anaphylaxis, have occurred during and immediately after IV and IM injection of phytonadione. Reactions have occurred despite dilution to avoid rapid IV infusion and upon first dose. Avoid the IV and IM routes of administration unless the SUBQ route is not feasible and the serious risk is justified.

Brand Names: US

Mephyton

Brand Names: Canada

AquaMEPHYTON;
Konakion;
Mephyton

Pharmacologic Category

Vitamin, Fat Soluble

Dosing: Adult

Note: Due to risk of a severe infusion reaction, including anaphylaxis, the maximum rate of IV administration is 1 mg/minute.

Reversal of anticoagulation due to warfarin or other coumarin or indandione derivatives

Reversal of anticoagulation due to warfarin or other coumarin or indandione derivatives:

Note: Dose and route depend on the severity of bleeding and/or INR.

Urgent reversal: IV administration is recommended. For life-threatening bleeding, vitamin K should be administered in combination with clotting factors (eg, 4-factor prothrombin complex concentrate [PCC], or fresh frozen plasma if 4-factor PCC is not available) (Ref). Following IV administration, reversal begins in ~2 hours with expected full reversal within 24 hours (Ref).

Nonurgent reversal: Oral administration is recommended to reduce INR in ~24 to 48 hours (Ref). Avoid other routes: SUBQ administration is not recommended due to unpredictable absorption (Ref). Avoid IM administration due to risk of hematoma formation.

Usual dosage range:

Oral: Initial: 2.5 to 10 mg, depending on the INR. Administer as a single dose. Measure INR after 12 to 48 hours and administer another dose as needed.

IV: Initial: 2.5 to 10 mg, depending on the INR and severity of bleeding. Administer as a single dose over 10 to 20 minutes (maximum infusion rate: 1 mg/minute). Measure INR after 6 to 12 hours and administer another dose as needed.

Note: High doses of vitamin K (eg, >10 to 15 mg) may cause warfarin resistance for ≥1 week; if anticoagulation is needed, an alternative agent may be necessary (Ref).

**Reversal of Anticoagulation From Warfarin**
Indication	Management considerations	Vitamin K administration
^a1 mg oral dose may be administered using 0.5 mL of 2 mg/mL parenteral preparation by mouth. ^bPatriquin 2011. ^cACCP [Hirsh 2008]. ^dACCP [Holbrook 2012]. ^eASH [Witt 2018]. ^fAHA/ACC [Nishimura 2014]; ACC/AHA [Otto 2021]. ^gFarrow 2020. ^hPCC=prothrombin complex concentrate. ⁱACCP [Ageno 2012]. ^jNCS/SCCM [Frontera 2016]. ^kACCP [Douketis 2022]. ^l Douketis 2021. ^m Hull 2022. ⁿ ACC [Doherty 2017]. ^o Nkomo 2023.
*Supratherapeutic INR and no evidence of bleeding*
INR above therapeutic range but <4.5	Consider holding the next dose of warfarin and/or reduce maintenance dose; increase INR monitoring. Elevated INR may be due to transient factors, so warfarin dose reduction is not always necessary.	Routine administration of vitamin K is not recommended.^b
INR 4.5 to 10	Discontinue warfarin, monitor INR frequently, and resume an appropriately reduced warfarin dose when INR is in desired range. May consider administering oral vitamin K if additional risk factors for bleeding exist.	Routine administration of vitamin K is not recommended. If administered, one dose of oral vitamin K 1 to 2.5 mg is recommended.^a,c,d,e,f
INR >10	Discontinue warfarin, monitor INR frequently, and resume an appropriately reduced warfarin dose when INR is in desired range. Consider administering oral vitamin K depending on bleeding and thrombotic risks.	If administered, one dose of oral vitamin K 2.5 to 5 mg is usually recommended; recheck INR after 12 to 24 hours; may administer a second dose if necessary.^c,d For patients with a mechanical prosthetic heart valve, a lower oral vitamin K dose of 1 to 2.5 mg may be administered to avoid overcorrection of INR.^a,f Some data suggest that vitamin K is not routinely needed in the absence of bleeding.^g
Bleeding
Minor bleeding	Discontinue warfarin, monitor INR frequently, and resume warfarin at an appropriately adjusted dose when it is safe to do so. Consider administering oral vitamin K depending on INR, site of bleeding, risk of progression to more serious bleeding, and thrombotic risk.	If administered, oral vitamin K 2.5 to 5 mg is recommended; if INR remains elevated after 24 hours, may administer another dose.^b
Major bleeding into a critical site and/or life- threatening bleeding (including intracranial hemorrhage)	Discontinue warfarin and urgently administer a 4-factor PCC^h in combination with IV vitamin K; monitor INR frequently and assess for hemostasis.	Administer IV vitamin K 10 mg over 10 to 20 minutes (maximum infusion rate: 1 mg/minute) as soon as possible in combination with a 4-factor PCC; if INR remains elevated after 12 to 24 hours, may administer another dose of vitamin K.^c,d,i,j
Invasive procedure or surgery
Elective	Thrombotic and bleeding risks vary depending on individual circumstances. Clinical practice guidelines may help guide whether to interrupt warfarin therapy, how long before an elective procedure or surgery warfarin should be discontinued (if necessary), whether bridging with a parenteral anticoagulant is needed, and when to restart warfarin therapy after the procedure/surgery.^k,n If it is decided to discontinue warfarin, therapy is typically stopped 5 days before the procedure/surgery. If INR remains >1.5 the day before the procedure/surgery, oral vitamin K may be considered but is not recommended routinely. Recheck INR on the day of the procedure/surgery.^l,k	Administer oral vitamin K 1 to 2.5 mg once if needed the day before the procedure/surgery.^a,b,l
Urgent	For urgent procedures or surgeries in patients at high bleeding risk, vitamin K with or without a 4-factor PCC may be needed.	Administer IV vitamin K 1 to 10 mg over 10 to 20 minutes (maximum infusion rate: 1 mg/minute) with or without a 4-factor PCC, depending on urgency of the procedure/surgery and risk of bleeding.^l,m For patients with a mechanical prosthetic heart valve, some experts recommend low-dose oral or IV vitamin K (ie, 1 or 2 mg) in combination with a 4-factor PCC in order to balance risk of bleeding and valve thrombosis.^o Refer to institutional policies and procedures.

Reversal of anticoagulation due to long-acting anticoagulant rodenticides

Reversal of anticoagulation due to long-acting anticoagulant rodenticides: Consultation with a clinical toxicologist or poison control center and hematologist is highly recommended when making treatment decisions, including dose, route, and duration of therapy (Ref).

No significant bleeding or minor bleeding (eg, epistaxis, ecchymosis):

Note: Ideal dosing has not been established.

INR <4 and no bleeding: No vitamin K required; monitor and observe closely (Ref).

INR >4 or minor bleeding: Oral: Some experts recommend an initial dose of 10 mg per day in otherwise healthy patients; titrate as needed based on serial PT and INR measurements (Ref). The reported daily dosage range is variable (up to 800 mg per day (Ref)). Patients may require treatment for several months and should be under the care of a hematologist (Ref); compliance with treatment and monitoring is of utmost importance during outpatient therapy (Ref).

Serious bleeding (eg, intracranial, GU, GI bleeding):

Note: Ideal dosing has not been established. For life-threatening bleeding, vitamin K should be administered in combination with clotting factors (eg, 4-factor prothrombin complex concentrate [PCC] or 3-factor PCC in combination with either recombinant factor VIIa or fresh frozen plasma if 4-factor PCC is not available) (Ref). Treatment should begin with IV vitamin K and then transition to oral therapy (Ref).

IV, Oral: Reported initial doses are variable and range from 10 to 300 mg per day; titrate as needed based on serial PT and INR measurements (Ref). Clinicians may choose to initiate therapy according to recommendations for reversal of anticoagulation due to warfarin or other coumarin or indandione derivatives at doses indicated for major bleeding at any INR elevation (Ref). The reported daily dosage range is variable (up to 800 mg per day (Ref)). Patients may require treatment with oral vitamin K for several months and should be under the care of a hematologist (Ref); compliance with treatment and monitoring is of utmost importance during outpatient therapy (Ref).

Vitamin K deficiency

Vitamin K deficiency (without liver disease):

Note: Vitamin K deficiency in healthy adults is rare; deficiency tends to be associated with specific conditions (eg, bariatric surgery, biliary disease, malnutrition, cystic fibrosis, prolonged use of broad-spectrum antibiotics) (Ref). Avoid oral route in situations associated with GI malabsorption.

Treatment of coagulopathy:

IV, Oral, SUBQ: Usual dose: 10 mg once; may repeat in 48 to 72 hours if coagulopathy persists (Ref); range: 1 to 25 mg (manufacturer's labeling); maximum IV infusion rate: 1 mg/minute (Ref). Note: SUBQ administration is not recommended in patients with generalized edema (eg, anasarca) (Ref).

Bariatric surgery:

Prevention of vitamin K deficiency, supplementation:

Laparoscopic adjustable gastric band, Roux-en-Y gastric bypass, or sleeve gastrectomy: Oral: 90 to 120 mcg once daily (Ref).

Biliopancreatic diversion/duodenal switch: Oral: 300 mcg once daily (Ref).

Acute vitamin K repletion for malabsorption:

IV: 10 mg once over 10 to 20 minutes (Ref).

Chronic vitamin K repletion for malabsorption:

IV: 1 to 2 mg once weekly (Ref).

Oral: 1 to 2 mg once daily (Ref).

Note: In the United States and Canada, low-dose oral preparations can be found over the counter. A pharmacist can help the patient locate a low-dose supplement from a reliable supplier or prepare a compounded oral solution.

Cystic fibrosis with pancreatic insufficiency:

Prevention of vitamin K deficiency, supplementation:

Oral: 2.5 to 5 mg once weekly. Note: Additional supplementation may be required during antibiotic therapy (Ref).

Liver disease, treatment of coagulopathy

Liver disease, treatment of coagulopathy (off-label use):

Note: Consider use if vitamin K deficiency is suspected (eg, due to poor nutrition, cholestatic disease, diarrheal illness, or antibiotic use); vitamin K does not correct clotting factor deficiency due to parenchymal liver dysfunction and is not typically used for variceal bleeding (Ref).

Major bleeding (nonvariceal): IV: 10 mg once over 10 to 20 minutes (maximum infusion rate: 1 mg/minute) (Ref).

Minor bleeding (nonvariceal):

Oral: 10 mg once daily for 3 days (Ref).

IV: 10 mg once over 10 to 20 minutes (maximum infusion rate: 1 mg/minute) (Ref).

Nonbleeding: Oral, IV, SUBQ: 5 to 10 mg once (maximum IV infusion rate: 1 mg/minute). Note: Oral route is preferred unless there is concern for poor absorption (Ref).

Warfarin-associated INR variation due to vitamin K deficiency

Warfarin-associated INR variation due to vitamin K deficiency (off-label use ):

Note: For use in patients with poor INR control due to suspected vitamin K deficiency (eg, insufficient dietary intake). Ensure proper warfarin adherence and consult with the anticoagulation specialist managing the patient before prescribing.

Oral: 100 to 200 mcg once daily (Ref).

Note: In the United States and Canada, low-dose (eg, 100 mcg) oral preparations can be found over the counter. A pharmacist can help the patient locate a low-dose supplement from a reliable supplier or prepare a compounded oral solution.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: No dosage adjustment necessary for any degree of kidney impairment (no unmetabolized vitamin K eliminated in urine) (Ref).

Hemodialysis, intermittent (thrice weekly): Unlikely to be significantly dialyzed (lipophilic characteristics) (Ref): No supplemental dose or dosage adjustment necessary (Ref).

Peritoneal dialysis: Unlikely to be significantly dialyzed (lipophilic characteristics): No dosage adjustment necessary (Ref).

CRRT: No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (Ref).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Vitamin K (phytonadione, phytomenadione): Pediatric drug information")

Note: Route of administration varies with indication; careful evaluation of route of administration is important. The oral route is preferred in the treatment of nonbleeding patients with warfarin-associated coagulopathy; SubQ administration has fallen out of favor for this indication due to erratic and unpredictable absorption (Ref). The IV route may be used in select nonbleeding patients and should be used in patients with major bleeding due to warfarin-associated coagulopathy (Ref). The IV and SubQ routes may be used in the treatment of vitamin K deficiency bleeding (Ref). The IM route should be avoided due to the risk of hematoma formation except in the prevention/treatment of vitamin K deficiency bleeding (Ref). Dosing presented in mcg and mg; verify dosing units.

Parenteral nutrition, maintenance requirement

Parenteral nutrition, maintenance requirement: Limited data available (Ref): Note: Patients receiving warfarin may not require TPN supplementation of phytonadione.

Infants: IV: 10 mcg/kg/day as an additive to parenteral nutrition solution.

Children and Adolescents: IV: 200 mcg/day as an additive to parenteral nutrition solution.

Reversal of vitamin K antagonists

Reversal of vitamin K antagonists (eg, warfarin): Limited data available:

Infants, Children, and Adolescents:

Weight-based dosing (preferred): Chest recommendations: IV: 0.03 mg/kg/dose is recommended for excessively prolonged INR (usually INR >8; no evidence of bleeding) due to vitamin K-antagonist (eg, warfarin): if significant bleeding, consider use of fresh frozen plasma, prothrombin complex concentrates, or recombinant factor VIIa (Ref).

Fixed dosing: Note: Smaller pediatric patients should receive doses on the low end of dosing range; excessive dosages may cause warfarin-resistance (Ref).

No bleeding, rapid reversal needed, patient will require further oral anticoagulant therapy: SubQ, IV: 0.5 to 2 mg.

No bleeding, rapid reversal needed, patient will not require further oral anticoagulant therapy: SubQ, IV: 2 to 5 mg.

Significant bleeding, not life-threatening: SubQ, IV: 0.5 to 2 mg; Note: Use in combination with fresh frozen plasma.

Significant bleeding, life-threatening: SubQ, IV: 5 mg; Note: Consider use with prothrombin complex concentrate containing factors II, VII, IX, X.

Vitamin K deficiency, prevention, and supplementation

Vitamin K deficiency, prevention, and supplementation (disease-specific): Limited data available:

Biliary atresia (Ref): Note: Dose and route are determined by INR value:

Infants 1 to 6 months:

INR >1.2 to 1.5: 2.5 mg once daily orally.

INR >1.5 to 1.8: Initial: 2 to 5 mg IM once followed by 2.5 mg once daily orally.

INR >1.8: Initial: 2 to 5 mg IM once followed by 5 mg once daily orally.

Cholestasis: Infants, Children, and Adolescents: Oral: 2.4 to 15 mg/day (Ref).

Cystic fibrosis: Infants, Children, and Adolescents: Oral: 0.3 to 0.5 mg/day (Ref).

Liver disease: Infants, Children, and Adolescents: Oral: 2.5 to 5 mg/day (Ref).

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in manufacturer's labeling; dosing adjustment unlikely necessary.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

Frequency not defined:

Cardiovascular: Chest pain, flushing, hypotension, tachycardia, weak pulse

Central nervous system: Dizziness

Dermatologic: Diaphoresis, eczematous rash, erythema, erythematous rash, pruritic plaques of the skin, urticaria

Gastrointestinal: Dysgeusia

Hepatic: Hyperbilirubinemia

Hypersensitivity: Anaphylactoid reaction, anaphylaxis, hypersensitivity reaction

Local: Injection site reaction (including pain, swelling, tenderness)

Respiratory: Cyanosis, dyspnea

Miscellaneous: Lesion (scleroderma-like)

Contraindications

Hypersensitivity to phytonadione or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Dermatologic toxicity: Cutaneous reactions have occurred after parenteral administration, including delayed-type hypersensitivity reactions, eczematous reactions, scleroderma-like patches, and urticaria; onset may occur within 1 day to a year. If skin reactions occur, discontinue therapy and treat appropriately.

• Hypersensitivity/anaphylactoid reactions: Hypersensitivity reactions, including anaphylaxis, chest pain, cyanosis, diaphoresis, dyspnea, flushing, cardiorespiratory arrest, shock, tachycardia, weakness, and death, have occurred. Anaphylaxis typically, but not always, occurred when patients received large IV doses administered rapidly with formulations containing polyethoxylated castor oil (also called polyoxyethylated castor oil); proper dosing, dilution, and administration will minimize risk (ACCP [Ageno 2012]; Britt 2018; Riegert-Johnson 2002).

Disease-related concerns:

• Anticoagulant-induced coagulopathy: In patients receiving a therapeutic vitamin K antagonist (VKA) (eg, warfarin), administer a dose of phytonadione that will quickly lower the INR into a safe range without causing resistance to warfarin. High phytonadione doses (eg, >10 to 15 mg) may lead to warfarin resistance for ≥1 week.

• Liver disease, coagulopathy: If initial doses do not reverse coagulopathy, then higher doses are unlikely to have any effect. Note: Ineffective in hereditary hypoprothrombinemia.

• Long-acting anticoagulant rodenticide (LAAR) ingestion: Patients with LAAR-induced coagulopathy require much larger doses and longer treatment durations (up to months) after exposure compared to that needed to reverse warfarin-induced coagulopathy (Devgun 2020; Gunja 2011).

Special populations:

• Neonates: Use with caution in neonates, especially premature infants; severe hemolytic anemia, jaundice, and hyperbilirubinemia have been reported with larger than recommended doses (10 to 20 mg).

Dosage form specific issues:

• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of >4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer's labeling.

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.

• Polyoxyethylated castor oil: Some injectable dosage forms contain polyoxyethylated castor oil (Cremophor EL) which is associated with hypersensitivity reactions.

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.

Other warnings/precautions:

• Appropriate route: Oral administration is the safest and requires the presence of bile salts for absorption. In obstructive jaundice or with biliary fistulas, concurrent administration of bile salts would be necessary for proper absorption. Manufacturers recommend the SubQ route over other parenteral routes, however, SubQ is less predictable when compared to the oral route, and efficacy may be delayed. Therefore, the SubQ route has fallen out of favor due to erratic and unpredictable absorption (Crowther 2002; DeZee 2006; Raj 1999). The IV route may be used in selected nonbleeding patients and should be used in patients with major bleeding due to warfarin-associated coagulopathy (ACCP [Guyatt 2012]; Patriquin 2011). IM route should be avoided due to the risk of hematoma formation (except, for example, in the neonatal and pediatric populations for prevention/treatment of vitamin K deficiency bleeding). Efficacy (eg, control of bleeding, decrease in INR) is delayed regardless of route of administration; patient management may require other treatments in the interim.

Dosage Forms Considerations

Injectable products may contain alcohol, benzyl alcohol, polysorbate 80, propylene glycol, or polyoxyethylated/polyethoxylated castor oil (Cremophor EL).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Injection, aqueous colloidal: 1 mg/0.5 mL (0.5 mL); 10 mg/mL (1 mL)

Injection, aqueous colloidal [preservative free]: 1 mg/0.5 mL (0.5 mL)

Tablet, oral:

Mephyton: 5 mg [scored]

Generic: 100 mcg, 5 mg

Generic Equivalent Available: US

Yes

Pricing: US

Capsules (K1-1000 Oral)

1 mg (per each): $0.11

Solution (Phytonadione Injection)

1 mg/0.5 mL (per 0.5 mL): $7.20 - $29.68

10 mg/mL (per mL): $51.32

Tablets (Phytonadione Oral)

5 mg (per each): $66.99

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Adult

IV: After dilution of dose in a minimum of 50 mL of compatible solution, administer slowly using an infusion pump over 10 to 20 minutes depending on dose at a rate not to exceed 1 mg/minute (Ref). The injectable route should be used only if the oral route is not feasible or there is a greater urgency to reverse anticoagulation. The IV route may be used in selected nonbleeding patients and should be used in patients with major bleeding due to warfarin-associated coagulopathy (Ref).

SUBQ: SUBQ route is generally not recommended due to erratic and unpredictable absorption (Ref).

IM: IM route should be avoided due to the risk of hematoma formation.

Oral: The parenteral formulation may also be used for small oral doses (eg, 1 mg) or situations in which tablets cannot be swallowed (Ref); may administer undiluted or diluted in a beverage (eg, orange juice) (Ref).

Administration: Pediatric

Oral: May be administered with or without food. The parenteral formulation may also be used for small oral doses (eg, 1 mg) or situations in which tablets cannot be swallowed (Ref).

Parenteral: Note: Limit IV administration to situations where an alternative route of administration is not feasible and the benefit of therapy outweighs the risk of hypersensitivity reactions; proper dosing, dilution, and administration will minimize risk (Ref). Allergic reactions have also occurred with IM and SUBQ injections, albeit less frequently.

SUBQ: Administer undiluted.

IM: Administer undiluted; for use in neonatal patients, verify appropriate concentration (1 mg/0.5 mL).

IV: After dilution, infuse slowly. In pediatric patients, IV doses have been infused over 10 to 30 minutes (Ref); maximum rate of infusion: 1 mg/minute (Ref).

Use: Labeled Indications

Reversal of anticoagulation due to warfarin or other coumarin or indandione derivatives (eg, brodifacoum): Treatment of anticoagulant-induced deficiency of vitamin K–dependent clotting factors caused by coumarin or indandione derivatives, including warfarin and long-acting anticoagulant rodenticides (eg, brodifacoum, bromadiolone, difenacoum) (Card 2014; Devgun 2020; Feinstein 2020; Gunja 2011).

Vitamin K deficiency (without liver disease): Treatment of deficiency secondary to factors limiting absorption or synthesis of vitamin K (eg, obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, regional enteritis) or drug-induced interference with vitamin K metabolism (eg, salicylates, antibacterial therapy).

Vitamin K deficiency bleeding (formerly known as hemorrhagic disease) of the newborn: Prophylaxis and treatment of vitamin K deficiency bleeding (formerly known as hemorrhagic disease) of the newborn (injection only).

Use: Off-Label: Adult

Liver disease, treatment of coagulopathy; Warfarin-associated INR variation due to vitamin K deficiency

Medication Safety Issues

Sound-alike/look-alike issues:

Mephyton may be confused with melphalan, methadone

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Orlistat: May decrease the absorption of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or 2 hours after the administration of orlistat. Avoid concomitant administration due to the risk of impaired vitamin absorption. Risk D: Consider therapy modification

Vitamin K Antagonists (eg, warfarin): Phytonadione may diminish the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Pregnancy Considerations

Phytonadione crosses the placenta in limited concentrations (Kazzi 1990).

The dietary requirements of vitamin K are the same in pregnant and nonpregnant women (IOM 2001). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003). Use of preservative free solutions are preferred when the injection is needed during pregnancy.

Breastfeeding Considerations

Phytonadione is present in breast milk.

Small amounts of dietary vitamin K can be detected in breast milk and the dietary requirements of vitamin K are the same in breastfeeding and non-breastfeeding women (IOM 2001). According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Use of preservative free solutions are preferred when the injection is needed in breastfeeding women.

Dietary Considerations

Dietary adequate intake (IOM 2001; Vanek 2012):

1 to 6 months: 2 mcg/day

7 to 12 months: 2.5 mcg/day

1 to 3 years: 30 mcg/day

4 to 8 years: 55 mcg/day

9 to 13 years: 60 mcg/day

14 to 18 years: 75 mcg/day

>18 years: Males: 120 mcg/day; Females: 90 mcg/day

Monitoring Parameters

Long-acting anticoagulant rodenticide poisoning: PT/INR; consider serial measurement of plasma coumarin concentration (eg, plasma brodifacoum concentrations) to help guide treatment duration decisions. At least 3 samples collected over the period of 1 week has been suggested to determine treatment duration; an additional measurement taken 2 weeks after treatment discontinuation is recommended to rule out rebound elevation and ensure maintenance of safe concentrations (Nosal 2021).

Mechanism of Action

Promotes liver synthesis of clotting factors (II, VII, IX, X); however, the exact mechanism as to this stimulation is unknown. Menadiol is a water soluble form of vitamin K; phytonadione has a more rapid and prolonged effect than menadione; menadiol sodium diphosphate (K₄) is half as potent as menadione (K₃).

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Increased coagulation factors: Oral: 6 to 10 hours; IV: 1 to 2 hours.

Peak effect: INR values return to normal: Oral: 24 to 48 hours; IV: 12 to 14 hours.

Absorption: Oral: From intestines in presence of bile; SUBQ: Variable; IM: Readily.

Metabolism: Rapidly hepatic.

Excretion: As metabolites in urine and feces.

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Konakion mm;
(AR) Argentina: Konakion mm | Vitamina k surar pharma | Vitamina k1 biol;
(AT) Austria: Konakion;
(BD) Bangladesh: Konakion;
(BE) Belgium: Konakion;
(BG) Bulgaria: Konakion;
(BR) Brazil: Kanakion | Kavit | Vita K | Vitamina k;
(CH) Switzerland: Konakion;
(CL) Chile: Fitoquinona | Konakion;
(CN) China: Kai nai jin | Vitamin K1;
(CO) Colombia: Fitomenadiona | Vitamina k | Vitamina K1;
(CZ) Czech Republic: Kanavit;
(DE) Germany: Kanavit | Vitamin K1;
(DO) Dominican Republic: Konakion;
(EC) Ecuador: Fitomenadiona | Konakion;
(EE) Estonia: Menadion medic;
(EG) Egypt: Adcokion | Epikavit | Haemokion | K Dion | K sabaa | Konakion | Origin k1 | Phytomenadion | Vitadione;
(GB) United Kingdom: Konakion mm;
(GR) Greece: Konakion;
(HK) Hong Kong: Vitamin K1;
(ID) Indonesia: Kaywan | Neo k;
(IE) Ireland: Konakion mm;
(IN) India: Kenadion;
(IT) Italy: Konakion;
(JP) Japan: Dekaywan | Ersupa k1 | Hymeron k1 | Kaywan | Keipole | Mephyton | Nichivita k1 | Onekey | Phytonadione merck | Phytonadione towa | Univitan k1 universal | Univitan k1 yoshindo | Vita k1 kobayashi | Vitamin k1 amel | Vitamin k1 daiko | Vitamin k1 fuso | Vitamin k1 meiji | Vitamin k1 mita | Vitamin k1 nipro | Vitamin k1 nisshin kyorin sei | Vitamin k1 pfizer | Vitamin k1 sawai | Vitamin k1 seiko | Vitamin k1 showa | Vitamin k1 taisho | Vitamin k1 tobishi;
(KR) Korea, Republic of: Kaywan;
(LB) Lebanon: Gnc Vitamin K | Konakion | Vitamin K;
(LT) Lithuania: Kanavit | Konakion | Konakion mm | Konakion novum;
(LV) Latvia: Kanavit;
(MX) Mexico: Amidalak;
(MY) Malaysia: Vitamin K | Vitamin K1;
(NO) Norway: Konakion | Menadion | Vitacon | Vitacon campus;
(NZ) New Zealand: Konakion mm | Vitamin K1;
(PE) Peru: Gnc Vitamin K;
(PH) Philippines: Hema-k;
(PK) Pakistan: Vitamin K1;
(PL) Poland: Kanavit;
(PR) Puerto Rico: Mephyton | Phytonadione | Vitamin K;
(PT) Portugal: Fitomenadiona | Kanakion | Kanakion MM | Kanakion Mm Pediatrico;
(PY) Paraguay: Fitoquinona;
(SA) Saudi Arabia: Amri k | Konakion;
(SE) Sweden: Konakion;
(SG) Singapore: Konakion mm;
(SK) Slovakia: Kanavit;
(TH) Thailand: K-vita | Konakion | Konakion mm;
(TN) Tunisia: Vitamine k1;
(TR) Turkey: Konakion;
(TW) Taiwan: Katimin-1 | Kaywan | Konakion mm | Phynadin k | Phytonadione | Vitamin K1;
(UY) Uruguay: Kavit | Konakion | Konakion mm | Vitamina k;
(VE) Venezuela, Bolivarian Republic of: Vitamina k | Vitamina K1;
(ZA) South Africa: Konakion

Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):e44s-e88s. doi:10.1378/chest.11-2292 [PubMed 22315269]
Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597. [PubMed 3960626]
Aluminum in large and small volume parenterals used in total parenteral nutrition. Fed Regist. 2002;67(244):77792-77793. To be codified at 21 CFR §201.323.
American Academy of Pediatrics Committee on Nutrition. Kleinman RE, Greer FR, eds. Pediatric Nutrition Handbook. 8th ed. American Academy of Pediatrics; 2019.
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6)(suppl):160s-198s. doi:10.1378/chest.08-0670 [PubMed 18574265]
Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? Birth Defects Res A Clin Mol Teratol. 2003;67(2):133-140. [PubMed 12769509]
Baugh CW, Levine M, Cornutt D, et al. Anticoagulant reversal strategies in the emergency department setting: recommendations of a multidisciplinary expert panel. Ann Emerg Med. 2020;76(4):470-485. doi:10.1016/j.annemergmed.2019.09.001 [PubMed 31732375]
Bolton-Maggs P, Brook L. The Use of Vitamin K for Reversal of Over-Warfarinization In Children. Br J Haematol. 2002;118(3):924. [PubMed 12181071]
Borowitz D, Baker RD, Stallings V. Consensus Report on Nutrition for Pediatric Patients With Cystic Fibrosis. J Pediatr Gastroenterol Nutr. 2002;35(3):246-259. [PubMed 12352509]
Britt RB, Brown JN. Characterizing the severe reactions of parenteral vitamin K1. Clin Appl Thromb Hemost. 2018;24(1):5-12. doi:10.1177/1076029616674825 [PubMed 28301903]
Bronsky J, Campoy C, Braegger C; ESPGHAN/ESPEN/ESPR/CSPEN working group on pediatric parenteral nutrition. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Vitamins. Clin Nutr. 2018;37(6, pt B):2366-2378. [PubMed 30100105]
Calello DP. Anticoagulant rodenticide poisoning: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 21, 2022.
Card DJ, Francis S, Deuchande K, Harrington DJ. Superwarfarin poisoning and its management. BMJ Case Rep. 2014;2014:bcr2014206360. doi:10.1136/bcr-2014-206360 [PubMed 25312896]
Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm. [PubMed 6423951]
Cozzolino M, Mangano M, Galassi A, Ciceri P, Messa P, Nigwekar S. Vitamin K in chronic kidney disease. Nutrients. 2019;11(1):168. doi:10.3390/nu11010168 [PubMed 30646590]
Croteau SE. Bleeding. In Eichenwald EC, Hansen AR, Martin CR, Stark AR. Cloherty and Stark's Manual of Neonatal Care. 9th edition. Lippincott Williams & Wilkins; 2022: chap. 43.
Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med. 2002;137(4):251-254. doi:10.7326/0003-4819-137-4-200208200-00009 [PubMed 12186515]
Crowther MA, Julian J, McCarty D, et al. Treatment of Warfarin-associated Coagulopathy With Oral Vitamin K: A Randomised Controlled Trial. Lancet. 2000;356(9241):1551-1553. [PubMed 11075768]
Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021 [PubMed 28669553]
Dentali F, Crowther M, Galli M, et al; WARPED Investigators. Effect of vitamin K intake on the stability of treatment with vitamin K antagonists: a systematic review of the literature. Semin Thromb Hemost. 2016;42(6):671-681. doi:10.1055/s-0036-1581105 [PubMed 27232386]
Devgun JM, Rasin A, Kim T, et al. An outbreak of severe coagulopathy from synthetic cannabinoids tainted with long-acting anticoagulant rodenticides. Clin Toxicol. 2020;58(8):821-828. doi:10.1080/15563650.2019.1690149 [PubMed 31797705]
DeZee KJ, Shimeall WT, Douglas KM, Shumway NM, O'Malley PG. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med. 2006;166(4):391-397. doi:10.1001/.391 [PubMed 16505257]
Doherty JU, Gluckman TJ, Hucker WJ, et al; 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2017; 69(7):871-898. doi:10.1016/j.jacc.2016.11.024 [PubMed 28081965]
Douketis JD, Lip GYH. Perioperative management of patients receiving anticoagulants. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 20, 2021.
Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):e326s-e350s. doi:10.1378/chest.11-2298 [PubMed 22315266]
Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. Chest. 2022;162(5):e207-e243. doi:10.1016/j.chest.2022.07.025 [PubMed 35964704]
Dror Y, Chan AKC, Baker JM, and Avila ML. Hematology. In: MacDonald MG, Seshia MMK, eds. Avery's Neonatology - Pathophysiology and Management of the Newborn. 7th ed. Philadelphia, PA: Wolters Kluwer; 2016:chap 43.
Eichenwald EC. Manual of Neonatal Care. 8th edition. Lippincott Williams & Wilkins; 2017.
Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
Farrow GS, Delate T, McNeil K, et al. Vitamin K versus warfarin interruption alone in patients without bleeding and an international normalized ratio >10. J Thromb Haemost. 2020;18(5):1133-1140. doi:10.1111/jth.14772 [PubMed 32073738]
Feinstein DL, Nosal DG, Ramanathan S, et al. Effects of vitamin K1 treatment on plasma concentrations of long-acting anticoagulant rodenticide enantiomers following inhalation of contaminated synthetic cannabinoids. Clin Toxicol (Phila). 2020;58(7):716-724. doi:10.1080/15563650.2019.1687903 [PubMed 31736367]
Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016;24(1):6-46. [PubMed 26714677]
Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. Nelson Textbook of Pediatrics. 18th ed. Saunders Elsevier; 2007: 2955-2999.
Gebuis EP, Rosendaal FR, van Meegen E, van der Meer FJ. Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study. Haematologica. 2011;96(4):583-589. doi:10.3324/haematol.2010.035162 [PubMed 21193422]
Gunja N, Coggins A, Bidny S. Management of intentional superwarfarin poisoning with long-term vitamin K and brodifacoum levels. Clin Toxicol (Phila). 2011;49(5):385-390. doi:10.3109/15563650.2011.587126 [PubMed 21740137]
Guyatt GH, Akl EA, Crowther M, et al. Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2)(suppl):7-47. [PubMed 22315257]
Hand I, Noble L, Abrams SA. Vitamin K and the newborn infant. Pediatrics. 2022;149(3):e2021056036. doi:10.1542/peds.2021-056036 [PubMed 35190810]
Hirsh J, Guyatt G, Albers GW, Harrington R, Schünemann HJ. Executive summary: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6)(suppl):71s-109s. doi:10.1378/chest.08-0693 [PubMed 18574259]
Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):e152s-e184s. doi:10.1378/chest.11-2295 [PubMed 22315259]
Hull RD, Garcia DA. Management of warfarin-associated bleeding or supratherapeutic INR. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 11, 2022.
"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
Intagliata N, Shah NL. Hemostatic abnormalities in patients with liver disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 30, 2021.
Institute of Medicine (IOM). Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. National Academy Press, 2001.
Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313. [PubMed 12534540]
Kazzi NJ, Ilagan NB, Liang KC, Kazzi GM, Grietsell LA, Brans YW. Placental transfer of vitamin K1 in preterm pregnancy. Obstet Gynecol. 1990;75(3, pt 1):334-337. [PubMed 2304704]
Kelkar AH, Smith NA, Martial A, Moole H, Tarantino MD, Roberts JC. An outbreak of synthetic cannabinoid-associated coagulopathy in Illinois. N Engl J Med. 2018;379(13):1216-1223. doi:10.1056/NEJMoa1807652 [PubMed 30280655]
Kliegman RM and St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Saunders Elsevier; 2020.
Kuramatsu JB, Sembill JA, Huttner HB. Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage. Crit Care. 2019;23(1):206. doi:10.1186/s13054-019-2492-8 [PubMed 31171018]
Lee WM, Larson AM, Stravitz RT. AASLD Position Paper: The management of acute liver failure: update 2011. Published September 2011. https://www.aasld.org/sites/default/files/2019-06/AcuteLiverFailureUpdate201journalformat1.pdf
Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172. [PubMed 10985636]
Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Surg Obes Relat Dis. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025 [PubMed 31917200]
Mephyton (phytonadione) [prescribing information]. Bridgewater, NJ: Bausch Health US LLC; July 2021.
Michelson AD, Bovill E, Monagle P, et al. Antithrombic Therapy in Children. Chest. 1998;114(5)(suppl):748-769. [PubMed 9822076]
Mihatsch WA, Braegger C, Bronsky J, et al. Prevention of vitamin K deficiency bleeding in newborn infants: a position paper by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2016;63(1):123-129. [PubMed 27050049]
Moia M, Squizzato A. Reversal agents for oral anticoagulant-associated major or life-threatening bleeding. Intern Emerg Med. 2019;14(8):1233-1239. doi:10.1007/s11739-019-02177-2 [PubMed 31446606]
Monagle P, Chan A, Goldenberg NA, et al. Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). Chest. 2012;141(2)(suppl):e737-e801. [PubMed 22315277]
Ng E, Loewy AD. Position Statement: Guidelines for vitamin K prophylaxis in newborns: A joint statement of the Canadian Paediatric Society and the College of Family Physicians of Canada. Can Fam Physician. 2018;64(10):736-739. [PubMed 30315016]
Nightingale S, Ng VL. Optimizing Nutritional Management in Children With Chronic Liver Disease. Pediatr Clin North Am. 2009;56(5):1161-1183. [PubMed 19931069]
Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(23):2440-2492. doi:10.1161/CIR.0000000000000029 [PubMed 24589852]
Nkomo VT, Konkle BA. Anticoagulation for prosthetic heart valves: management of bleeding and invasive procedures. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 2, 2023.
Nosal DG, van Breemen RB, Haffner JW, Rubinstein I, Feinstein DL. Brodifacoum pharmacokinetics in acute human poisoning: implications for estimating duration of vitamin K therapy. Toxicol Commun. 2021;5(1):69-72. doi:10.1080/24734306.2021.1887637 [PubMed 33768191]
O'Connor ME, Addiego JE. Use of Oral Vitamin K1 to Prevent Hemorrhagic Disease of the Newborn Infant. J Pediatr. 1986;108(4):616-619. [PubMed 3514830]
O'Leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA clinical practice update: coagulation in cirrhosis. Gastroenterology. 2019;157(1):34-43.e1. doi:10.1053/j.gastro.2019.03.070 [PubMed 30986390]
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e72-e227. doi:10.1161/CIR.0000000000000923 [PubMed 33332150]
Patriquin C, Crowther M. Treatment of warfarin-associated coagulopathy with vitamin K. Expert Rev Hematol. 2011;4(6):657-665. doi:10.1586/ehm.11.59 [PubMed 22077529]
Pazirandeh S, Burns DL. Overview of vitamin K. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 28, 2020.
Pereira SP, Rowbotham D, Fitt S, Shearer MJ, Wendon J, Williams R. Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease. J Hepatol. 2005;42(3):365-370. [PubMed 15710219]
Phytonadione injectable emulsion [prescribing information]. South El Monte, CA: International Medication Systems Ltd; December 2021.
Phytonadione injectable emulsion [prescribing information]. Warren, NJ: Cipla USA Inc; March 2022.
Phytonadione injection [prescribing information]. Lake Forest, IL: Hospira Inc; April 2021.
Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med. 1999;159(22):2721-2724. doi:10.1001/archinte.159.22.2721 [PubMed 10597763]
Reese AM, Farnett LE, Lyons RM, Patel B, Morgan L, Bussey HI. Low-dose vitamin K to augment anticoagulation control. Pharmacotherapy. 2005;25(12):1746-1751. doi:10.1592/phco.2005.25.12.1746 [PubMed 16305294]
Refer to manufacturer's labeling.
Rice JH, Akpunonu P, Davis GA, et al. Intravenous phytonadione administered orally in reducing warfarin-related coagulopathy. Clin Toxicol. 2022;60(4):530-532. doi:10.1080/15563650.2021.1995871 [PubMed 34751053]
Riegert-Johnson DL, Volcheck GW. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann Allergy Asthma Immunol. 2002;89(4):400-406. [PubMed 12392385]
Rombouts EK, Rosendaal FR, Van Der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost. 2007;5(10):2043-2048. doi:10.1111/j.1538-7836.2007.02715.x [PubMed 17666020]
Sathe MN, Patel AS. Update in Pediatrics: Focus on Fat-Soluble Vitamins. Nutr Clin Pract. 2010;25(4):340-346. [PubMed 20702838]
Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood. 2007;109(6):2419-2423. doi:10.1182/blood-2006-09-049262 [PubMed 17110451]
Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313. [PubMed 7746084]
Shneider BL, Magee JC, Bezerra JA, et al. Efficacy of Fat-Soluble Vitamin Supplementation in Infants With Biliary Atresia. Pediatrics. 2012;130(3):e607-e614. [PubMed 22891232]
Stravitz RT, Ellerbe C, Durkalski V, et al; Acute Liver Failure Study Group. Bleeding complications in acute liver failure. Hepatology. 2018;67(5):1931-1942. doi:10.1002/hep.29694 [PubMed 29194678]
Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(5):594-622. doi:10.1016/j.jacc.2020.04.053 [PubMed 32680646]
Tsutaoka BT, Miller M, Fung SM, Patel MM, Olson KR. Superwarfarin and glass ingestion with prolonged coagulopathy requiring high-dose vitamin K1 therapy. Pharmacotherapy. 2003;23(9):1186-1189. doi:10.1592/phco.23.10.1186.32755 [PubMed 14524650]
Vanek VW, Borum P, Buchman A, et al. A.S.P.E.N. Position Paper: Recommendations for Changes in Commercially Available Parenteral Multivitamin and Multi-trace Element Products. Nutr Clin Pract. 2012;27(4):440-491. [PubMed 22730042]
Vanier MC, Ngo TT. Reversal of overanticoagulation with vitamin K1: A plea for oral administration. Can J Hosp Pharm. 2006;59:125-135.
Vitamin K₁ (phytonadione) injectable emulsion [prescribing information]. Lake Forest, IL: Hospira; April 2018.
Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018;2(22):3257-3291. doi:10.1182/bloodadvances.2018024893 [PubMed 30482765]
Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest. 2004;125(1)(suppl):1s-39s. doi:10.1378/chest.125.1_suppl.1s [PubMed 14734689]

Topic 9771 Version 233.0

خرید پکیج

Vitamin K (phytonadione, phytomenadione): Drug information